Strategies to Optimize Molecularly Targeted Anti-Cancer Agent Combinations
Cytotoxic agents which are used in cancer chemotherapy reduced several times the number of neoplastic cells but not fully. Therefore, usage of and ldquo;targeted therapeutics" which were developed with much more rational approach is increasing markedly in patients with solid cancer. Targeted t...
Main Authors: | , |
---|---|
Format: | Article |
Language: | Turkish |
Published: |
Cukurova University Faculty of Medicine
2015-12-01
|
Series: | Arsiv Kaynak Tarama Dergisi |
Subjects: | |
Online Access: | http://www.scopemed.org/fulltextpdf.php?mno=179237 |
id |
doaj-259b6b75e67843beab08d1ab2b75a401 |
---|---|
record_format |
Article |
spelling |
doaj-259b6b75e67843beab08d1ab2b75a4012020-11-25T00:26:11ZturCukurova University Faculty of MedicineArsiv Kaynak Tarama Dergisi1300-37552015-12-01244432451179237Strategies to Optimize Molecularly Targeted Anti-Cancer Agent CombinationsAyse Erdogan0Aysun Ozkan1Akdeniz Universitesi, Fen Fakultesi, Biyoloji Bolumu, 07058, Antalya, TURKiYE/ TURKEY Akdeniz Universitesi, Fen Fakultesi, Biyoloji Bolumu, 07058, Antalya, TURKiYE/ TURKEYCytotoxic agents which are used in cancer chemotherapy reduced several times the number of neoplastic cells but not fully. Therefore, usage of and ldquo;targeted therapeutics" which were developed with much more rational approach is increasing markedly in patients with solid cancer. Targeted therapeutics due to selective targets aims cancer cells with specific molecular defect thereby, kils the cancer cells, which makes it possible to continue normal cells in a healthy environment. The rapid emergence of hundreds of new agents that modulates ever-growing list of the cancer-specific molecular targets promise great hope for cancer patients. Evaluation of the target agent individually, in combination with standard therapy and other target agents bring about important development challenges. As possible combinations of drugs number is unlimited, the identification of the most promising combinations and giving priority to assessing their strategies are very important.In this article important elements of the development strategy of the target agent combinations will be considered. Difficulties in this kind of combinations of rational pre-clinical and clinical evaluation and possible approaches to overcome these challenges will be discussed. [Archives Medical Review Journal 2015; 24(4.000): 432-451]http://www.scopemed.org/fulltextpdf.php?mno=179237Molecularly targeted anti-cancer agentscancer therapeutic targets |
collection |
DOAJ |
language |
Turkish |
format |
Article |
sources |
DOAJ |
author |
Ayse Erdogan Aysun Ozkan |
spellingShingle |
Ayse Erdogan Aysun Ozkan Strategies to Optimize Molecularly Targeted Anti-Cancer Agent Combinations Arsiv Kaynak Tarama Dergisi Molecularly targeted anti-cancer agents cancer therapeutic targets |
author_facet |
Ayse Erdogan Aysun Ozkan |
author_sort |
Ayse Erdogan |
title |
Strategies to Optimize Molecularly Targeted Anti-Cancer Agent Combinations |
title_short |
Strategies to Optimize Molecularly Targeted Anti-Cancer Agent Combinations |
title_full |
Strategies to Optimize Molecularly Targeted Anti-Cancer Agent Combinations |
title_fullStr |
Strategies to Optimize Molecularly Targeted Anti-Cancer Agent Combinations |
title_full_unstemmed |
Strategies to Optimize Molecularly Targeted Anti-Cancer Agent Combinations |
title_sort |
strategies to optimize molecularly targeted anti-cancer agent combinations |
publisher |
Cukurova University Faculty of Medicine |
series |
Arsiv Kaynak Tarama Dergisi |
issn |
1300-3755 |
publishDate |
2015-12-01 |
description |
Cytotoxic agents which are used in cancer chemotherapy reduced several times the number of neoplastic cells but not fully. Therefore, usage of and ldquo;targeted therapeutics" which were developed with much more rational approach is increasing markedly in patients with solid cancer. Targeted therapeutics due to selective targets aims cancer cells with specific molecular defect thereby, kils the cancer cells, which makes it possible to continue normal cells in a healthy environment. The rapid emergence of hundreds of new agents that modulates ever-growing list of the cancer-specific molecular targets promise great hope for cancer patients. Evaluation of the target agent individually, in combination with standard therapy and other target agents bring about important development challenges. As possible combinations of drugs number is unlimited, the identification of the most promising combinations and giving priority to assessing their strategies are very important.In this article important elements of the development strategy of the target agent combinations will be considered. Difficulties in this kind of combinations of rational pre-clinical and clinical evaluation and possible approaches to overcome these challenges will be discussed. [Archives Medical Review Journal 2015; 24(4.000): 432-451] |
topic |
Molecularly targeted anti-cancer agents cancer therapeutic targets |
url |
http://www.scopemed.org/fulltextpdf.php?mno=179237 |
work_keys_str_mv |
AT ayseerdogan strategiestooptimizemolecularlytargetedanticanceragentcombinations AT aysunozkan strategiestooptimizemolecularlytargetedanticanceragentcombinations |
_version_ |
1725345546358489088 |